Position in LPCN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$3,595,500
-$660,400 QoQ
Shares Held
450,000
-15.1% QoQ
Ownership
5.46%
of shares outstanding
% of Portfolio
1.44%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LPCN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Squadron Capital Management LLC holds $242,134,271 across 28 Biotechnology names. LPCN ranks #18 (1.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RLMD |
Relmada Therapeutics, Inc.
|
8,474,571 | $58,983,014 | |
| 2 | COGT |
Cogent Biosciences, Inc.
|
787,492 | $30,310,567 | |
| 3 | KALV |
KalVista Pharmaceuticals, Inc.
|
985,100 | $19,830,063 | |
| 4 | KOD |
Kodiak Sciences Inc.
|
380,000 | $14,485,600 | |
| 5 | ABVX |
Abivax S.A.
|
130,000 | $14,475,500 | |
| 6 | EWTX |
Edgewise Therapeutics, Inc.
|
350,000 | $11,025,000 | |
| 7 | NKTR |
Nektar Therapeutics
|
125,000 | $8,993,750 | |
| 8 | ANL |
Adlai Nortye Ltd.
|
1,265,231 | $8,755,398 |
All Filings in LPCN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,595,500 | 450,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $4,255,900 | 530,000 | Shares | Sole | 2026-02-17 | |
| 2025-12-18 | $2,100,000 | 500,000 | Shares | Sole | 2025-12-23 | |
| No filing history on record for this holder in this stock. | ||||||